The 23K variant of the R23K polymorphism in the glucocorticoid receptor gene protects against postnatal growth failure and insulin resistance after preterm birth

Martijn J. J. Finken, Ingrid Meulenbelt, Friedo W. Dekker, Marijke Frölich, Johannes A. Romijn, P. Eline Slagboom, Jan M. Wit

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)


Context: Preterm birth is associated with postnatal growth failure, abdominal fat accumulation, insulin resistance, and hypertension, resembling increased glucocorticoid bioactivity. Objective: We tested the effects of the R23K and N363S polymorphisms in the glucocorticoid receptor gene, associated with decreased and increased sensitivity to cortisol, respectively, on linear growth and the adult metabolic profile in a cohort (n = 249) of men and women born less than 32 gestational weeks and followed up prospectively from birth until 19 yr of age. Designand Participants: Thiswasabirth cohort study that included249 19-yr-old survivors born at a gestational age less than 32 wk from the Dutch Project on Preterm and Small-for-Gestational-Age Infants cohort. Setting: This project was a nationwide multicenter follow-up study. Main Outcome Measures: Linear growth and adult body composition, fasting cortisol, glucose, insulin, and cholesterol concentrations, and blood pressure were measured. Results: The 23K variant (n = 24) was associated with lower fasting insulin levels [mean difference after log transformation: -0.09 (95% confidence interval -0.16, -0.01) mU/liter] and a lower homeostatic model assessment for insulin resistance index [mean difference after log transformation: -0.09 (95% confidence interval -0.16, -0.01)] as well as with a taller stature departing from the age of 1 yr onward. 23K carriers showed complete catch-up growth between the ages of 3 months and 1 yr, and attained height was similar to the population reference mean, whereas stature in noncarriers was on average 0.5 SD below this mean. In contrast, the N363S polymorphism was not associated with any of the outcomes. Conclusions: Carriers of the 23K variant are, at least in part, protected against postnatal growth failure and insulin resistance after preterm birth. Copyright © 2007 by The Endocrine Society.
Original languageEnglish
Pages (from-to)4777-4782
JournalJournal of clinical endocrinology and metabolism
Issue number12
Publication statusPublished - 2007

Cite this